FDA experts advise stronger warning labels for flu drugs

An FDA panel on Tuesday recommended that Roche change warning labels on influenza drug Tamiflu to include information on the death of several patients who developed psychiatric problems after treatment. The committee also suggested additional warnings about the risk of delirium, hallucinations and psychotic behavior linked to GlaxoSmithKline's Relenza. Roche said it hasn't found evidence that its drug caused such side effects but would continue to study the issue, and Glaxo also said there was no evidence of a link with its drug.

View Full Article in:

Bloomberg1 · NYTimes.com · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA